IN10018 + furmonertinib

IN10018 + furmonertinib is a combination of two investigational small molecule drugs under clinical investigation for the treatment of non-small cell lung cancer (NSCLC) and potentially other solid tumors. **Furmonertinib** is a third-generation, oral, mutant-selective EGFR tyrosine kinase inhibitor (TKI) with strong activity against classic EGFR-activating mutations, T790M resistance mutation, and certain EGFR exon 20 insertions, displaying high central nervous system (brain) penetration and activity. **IN10018** is a selective focal adhesion kinase (FAK) inhibitor, thought to disrupt the tumor microenvironment and inhibit cancer cell survival and metastasis by targeting FAK, a protein involved in cellular adhesion and signaling. The rationale for this combination is based on potential synergistic antitumor activity by inhibiting both EGFR and FAK pathways, which are implicated in growth, survival, and metastasis of various cancers, including those resistant to EGFR TKI monotherapy.

Other names

IN10018 + furmonertinib